Seer, Inc. develops and commercializes research-use proteomics products centered on its Proteograph Product Suite. The suite integrates proprietary engineered nanoparticles, optimized consumables, automation instrumentation and analytical software for proteomic analysis in research laboratories, academic institutions and biopharmaceutical settings.
SEER news commonly covers financial results and outlook, Proteograph adoption, research collaborations in multi-omic and population-scale studies, intellectual-property developments involving particle-based protein enrichment, and commercial leadership changes. Company updates also include governance and shareholder matters, including board responses to unsolicited proposals, director nominations, rights plans and other capital-structure actions.
Summary not available.
Seer (Nasdaq: SEER) will provide its Proteograph product suite to deeply profile the plasma proteome in 10,000 PRECISE-SG100K participant samples, integrated with Thermo Fisher Olink Reveal and Orbitrap Astral data.
The collaboration aims to add deep, unbiased proteomics to a ~100,000-person, multi-ancestry Singapore cohort to support biomarker discovery, drug target biology, and population-level risk models.
Seer (Nasdaq: SEER) said the U.S. Patent and Trademark Office Patent Trial and Appeal Board issued a Final Written Decision on March 23, 2026 upholding 23 claims of U.S. Patent No. 11,435,360, which protect its Proteograph nanoparticle protein enrichment methods.
The ’360 patent is owned by Brigham and Women’s Hospital and exclusively licensed to Seer; the decision affirms key claim coverage of Proteograph’s nano- and microparticle protein-corona technology.
Seer noted the platform is supported by an IP portfolio of more than 240 issued and pending patents, including 80 issued patents.
Summary not available.
Seer (Nasdaq: SEER) adopted a limited-duration tax benefit preservation plan to protect approximately $262 million of net operating loss carryforwards as of December 31, 2025. The plan seeks to limit ownership accumulation above 4.9% of Class A stock without Board approval.
The Board declared a dividend of one transferable right per outstanding Class A share, with a record date of March 9, 2026. The NOL Plan expires February 25, 2029, or earlier on February 25, 2027 if shareholders do not ratify it at Seer’s 2026 annual meeting.
Seer (Nasdaq: SEER) reported fourth-quarter and full-year 2025 results, with $4.2M revenue in Q4 and $16.6M for full year 2025. Installed base grew to 82 instruments (67% YoY) and year-end cash, cash equivalents and investments were approximately $240.6M.
Gross margin was ~51% for 2025, operating expenses fell to $86.5M, and net loss narrowed to $73.6M. Seer expects 2026 revenue of $16M–$18M (midpoint ~3% growth).
Radoff-JEC Group (owners of ~7.5% of SEER) sent an open letter to Seer (NASDAQ: SEER) on February 23, 2026, pressing for immediate governance and operational change.
The letter cites a >96% share price decline since Seer’s 2020 IPO, 2025 revenue midpoint of $17.5M, cumulative cash used in operations of $138.8M and capex of $11.4M (total cash use $150.2M), a market cap of $110.5M vs. $251.2M net cash, and CEO Omid Farokhzad’s reported total compensation of $24.9M (2021–2024).
Seer (NASDAQ: SEER) will participate in US HUPO 2026 in St. Louis, Feb 21–25, showcasing the Proteograph Product Suite across posters, oral sessions, and a breakfast symposium on Feb 24. Presentations span cardiovascular disease, neurodegeneration, aging biology, oncology, and population-scale proteomics, highlighting deep, scalable nanoparticle-enabled proteomics.
Speakers include Sasha A. Singh, Nathan Basisty, Bruce Wilcox, and Mozhgan Boroumand; Singh reports quantifying >5,000 proteins from 75 µL plasma per sample.
Seer (Nasdaq: SEER) will participate in the TD Cowen 46th Annual Health Care Conference in Boston on March 4, 2026. Management will take part in a fireside chat at 11:10 a.m. ET, with a live webcast and archived replay available on the company website.
Seer (Nasdaq: SEER) will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. Management will host a live webcast and conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Live audio and an archived replay will be available on the company investor website.